116476-16-5|Levosemotiadil|(S)-2-(2-(3-((2-(benzo[d][1,3]dioxol-5-yloxy)ethyl)(methyl)amino)propoxy)-5-methoxyphenyl)-4-methyl-2H-benzo[b][1,4]thiazin-3(4H)-one|-范德生物科技公司

Levosemotiadil

NMR下载 COA and HPLC MSDS下载
names：
(S)-2-(2-(3-((2-(benzo[d][1,3]dioxol-5-yloxy)ethyl)(methyl)amino)propoxy)-5-methoxyphenyl)-4-methyl-2H-benzo[b][1,4]thiazin-3(4H)-one
CAS号：
116476-16-5
MDL Number：
MF(分子式)： C29H32N2O6S MW(分子量)： 536.64
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	Levosemotiadil
英文别名	Levosemotiadil;
CAS号	116476-16-5
Inchi	InChI=1S/C29H32N2O6S/c1-30(14-16-34-21-10-12-25-26(18-21)37-19-36-25)13-6-15-35-24-11-9-20(33-3)17-22(24)28-29(32)31(2)23-7-4-5-8-27(23)38-28/h4-5,7-12,17-18,28H,6,13-16,19H2,1-3H3/t28-/m0/s1
InchiKey	RKXVEXUAWGRFNP-NDEPHWFRSA-N
分子式 Formula	C29H32N2O6S
分子量 Molecular Weight	536.64
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Levosemotiadil(CAS:116476-16-5):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Levosemotiadil is an antiarrhythmic agent with vasodilator properties.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Adamson PB, Vanoli E, Shibano T, Foreman RD, Schwartz PJ. Combined sodium and calcium channel blockade in prevention of lethal arrhythmias. J Cardiovasc Pharmacol. 2003 May;41(5):665-70. PubMed PMID: 12717095.

[2]Ueda K, Yamaoka K, Rodriguez ME, Shibukawa A, Nakagawa T. Enantioselective local disposition of semotiadil (R-enantiomer) and levosemotiadil (S-enantiomer) in perfused rat liver. Drug Metab Dispos. 1997 Mar;25(3):281-6. PubMed PMID: 9172944.

[3] Rodriguez Rosas ME, Shibukawa A, Yoshikawa Y, Kuroda Y, Nakagawa T. Binding study of semotiadil and levosemotiadil with alpha(1)-acid glycoprotein using high-performance frontal analysis. Anal Biochem. 1999 Oct 1;274(1):27-33. PubMed PMID: 10527493.

[4] Rodriguez Rosas ME, Shibukawa A, Ueda K, Nakagawa T. Enantioselective protein binding of semotiadil and levosemotiadil determined by high-performance frontal analysis. J Pharm Biomed Anal. 1997 Jun;15(9-10):1595-601. PubMed PMID: 9226594.

[5] Sasaki S, Nakagawa M. [Calcium channel blocker for therapy of patients with hypertension]. Nihon Rinsho. 1997 Aug;55(8):2061-6. Review. Japanese. PubMed PMID: 9284424.

6: Fujiki A, Tani M, Hayashi H, Mizumaki K, Inoue H, Uemura H, Nakaya H. Electrophysiologic effects of SD-3212, a new class I antiarrhythmic drug, on canine atrial flutter and atrial action-potential characteristics. J Cardiovasc Pharmacol. 1997 Apr;29(4):471-5. PubMed PMID: 9156356.7: Wolfram RM, Kritz H, Oguogho A, Sinzinger H. Antiplatelet activity of semotiadil fumarate. Thromb Res. 2002 May 15;106(4-5):187-90. PubMed PMID: 12297124.8: Nishiyama A, Tamaki T, Masumura H, He H, Kiyomoto H, Aki Y, Yamamoto A, Iwao H, Abe Y. Effects of semotiadil fumarate (SD-3211) on renal hemodynamics and function in dogs. Eur J Pharmacol. 1992 Aug 6;218(2-3):311-7. PubMed PMID: 1425946.9: Takahashi N, Ito M, Ishida S, Fujino T, Maruyama T, Saikawa T. Electrophysiological effects of SD-3212, a novel antiarrhythmic agent, on rabbit hearts in vivo and in vitro. J Cardiovasc Pharmacol. 1995 Jun;25(6):1006-11. PubMed PMID: 7564327.10: Koidl B, Miyawaki N, Tritthart HA. A novel benzothiazine Ca2+ channel antagonist, semotiadil, inhibits cardiac L-type Ca2+ currents. Eur J Pharmacol. 1997 Mar 19;322(2-3):243-7. PubMed PMID: 9098694.1

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开